IL305250A - Combination of RAF inhibitor and MEK inhibitor - Google Patents

Combination of RAF inhibitor and MEK inhibitor

Info

Publication number
IL305250A
IL305250A IL305250A IL30525023A IL305250A IL 305250 A IL305250 A IL 305250A IL 305250 A IL305250 A IL 305250A IL 30525023 A IL30525023 A IL 30525023A IL 305250 A IL305250 A IL 305250A
Authority
IL
Israel
Prior art keywords
braf
subject
cancer
administered
compound
Prior art date
Application number
IL305250A
Other languages
English (en)
Hebrew (he)
Original Assignee
Day One Biopharmceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Day One Biopharmceuticals Inc filed Critical Day One Biopharmceuticals Inc
Publication of IL305250A publication Critical patent/IL305250A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL305250A 2021-02-19 2022-02-18 Combination of RAF inhibitor and MEK inhibitor IL305250A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163151425P 2021-02-19 2021-02-19
US202163173158P 2021-04-09 2021-04-09
PCT/US2022/016962 WO2022178244A1 (en) 2021-02-19 2022-02-18 Combination of raf inhibitor and mek inhibitor

Publications (1)

Publication Number Publication Date
IL305250A true IL305250A (en) 2023-10-01

Family

ID=82931723

Family Applications (1)

Application Number Title Priority Date Filing Date
IL305250A IL305250A (en) 2021-02-19 2022-02-18 Combination of RAF inhibitor and MEK inhibitor

Country Status (10)

Country Link
US (1) US20240058338A1 (https=)
EP (1) EP4294400A4 (https=)
JP (1) JP2024507221A (https=)
KR (1) KR20230147136A (https=)
AU (1) AU2022223437A1 (https=)
CA (1) CA3211167A1 (https=)
IL (1) IL305250A (https=)
MX (1) MX2023009642A (https=)
WO (1) WO2022178244A1 (https=)
ZA (1) ZA202307921B (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4408430A4 (en) * 2021-10-01 2025-07-30 Day One Biopharmaceuticals Inc RAF KINASE INHIBITORS FOR THE TREATMENT OF TUMORS WITH GENE FUSIONS
WO2025106686A1 (en) * 2023-11-15 2025-05-22 Day One Biopharmaceuticals, Inc. Methods of treating pediatric low-grade glioma

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104428001A (zh) * 2012-03-30 2015-03-18 武田药品工业有限公司 Raf抑制剂和mek抑制剂在黑素瘤治疗中的投与
CA3240745A1 (en) * 2013-12-20 2015-06-25 Biomed Valley Discoveries, Inc. Cancer treatment using combinations of erk and raf inhibitors
UY36046A (es) * 2014-03-26 2015-10-30 Millennium Pharm Inc Formulaciones farmacéuticas, procesos para la preparación y métodos de uso
WO2016025648A1 (en) * 2014-08-13 2016-02-18 Celgene Avilomics Research, Inc. Combinations of an erk inhibitor and a raf inhibitor and related methods
AU2018329925B2 (en) * 2017-09-08 2025-05-29 F. Hoffmann-La Roche Ag Diagnostic and therapeutic methods for cancer

Also Published As

Publication number Publication date
ZA202307921B (en) 2024-04-24
EP4294400A1 (en) 2023-12-27
WO2022178244A1 (en) 2022-08-25
MX2023009642A (es) 2023-10-16
EP4294400A4 (en) 2025-01-01
US20240058338A1 (en) 2024-02-22
AU2022223437A1 (en) 2023-09-07
CA3211167A1 (en) 2022-08-25
KR20230147136A (ko) 2023-10-20
JP2024507221A (ja) 2024-02-16

Similar Documents

Publication Publication Date Title
JP7681910B2 (ja) Ｎｒａｓ変異を有する腫瘍を治療するための医薬品の調製におけるｆａｋ阻害剤の使用
US20120295937A1 (en) Nitroxide therapy for the treatment of von hippel - lindau disease (vhl) and renal clear cell carcinoma (rcc)
US20240058338A1 (en) Combination of raf inhibitor and mek inhibitor
AU2016246521A1 (en) Treatment of lung cancer with inhibitors of glutaminase
JP2020517696A (ja) Ｈｅｒ２陽性がんの処置
CN110996960A (zh) 第三代egfr酪氨酸激酶抑制剂和raf抑制剂的治疗组合
US20230277522A9 (en) Methods for treating vascular malformations
BR112021012132A2 (pt) Derivados de quinolina para uso no tratamento ou prevenção de câncer
Shim et al. Intraoperative multimodal analgesic bundle containing dexmedetomidine and ketorolac may improve analgesia after robot-assisted prostatectomy in patients receiving rectus sheath blocks
EA015933B1 (ru) Лечение детских опухолей
US20230358726A1 (en) Non-invasive functional companion assays for oncogene targeted therapy for brain cancer
EP4013417A1 (en) Methods and compositions for treating vascular malformations
JP2016069348A (ja) 慢性骨髄性白血病の治療用組成物
CN117177754A (zh) Raf抑制剂和mek抑制剂的组合
TW202339767A (zh) 螺環芳基磷氧化物與抗ｅｇｆｒ抗體的聯用藥物組合物及其用途
JP2015512416A (ja) 神経芽細胞腫、ユーイング肉腫または横紋筋肉腫の治療に使用するための化合物
US20250339412A1 (en) Methods of treating solid tumor using (19r)-5-chloro-3-ethyl-16-fluoro-10,19-dimethyl-20-oxa-3,4,10,11,23-pentaazapentacyclo[19.3.1.02,6.08,12.013,18]pentacosa-1(24),2(6),4,8,11,13,15,17,21(25),22-decaen-22-amine
RU2811417C2 (ru) Производные хинолина для применения в лечении или предупреждении рака
Potapenko et al. CRIZOTINIB IN TREATMENT OF ATYPICAL ALK-REARRANGED HISTIOCYTE-RICH TUMOR. CASE REPORT
Meidutė The effect of physical activity and folk dance on balance
JP2023178473A (ja) 小児患者のがんの治療方法
TW202502341A (zh) 哌啶烯類化合物在製備治療癌症的藥物中的應用
WO2022271907A1 (en) Erk1/2 and egfr inhibitors combination therapy
CN121895326A (zh) 一种泛kras突变抑制剂及其应用
HK40118235A (zh) 用於治疗或预防癌症的喹啉衍生物